Pilot study of sorafenib for RET fusion positive non-small cell lung cancer
Not Applicable
- Conditions
- RET fusion positive non-small cell lung cancer
- Registration Number
- JPRN-UMIN000007515
- Lead Sponsor
- Japanese Foundation for Cancer Research Cancer Institute Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 3
Inclusion Criteria
Not provided
Exclusion Criteria
1)Serious complications 2)Brain metastases need raidotherapy 3)Subjects with interstitial pneumonia or pulmonary fibrosis by chest X-ray 4)Patients who can not take orally. 5)Patients who have serious hypersensitivity reaction. 6)Patients who receive prohibited treatments. 7)Pregnancy, breast feeding or wish of future bearing 8)Concurrent use of steriod therapy except for topical or inhaled 9)Active infectious disease 10)Pleural effusion, peritoneal fluid, and pericardial fluid need drainage therapy 11)Patients whose participation in the trial is judged to be inappropriate by the attending doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method feasibility
- Secondary Outcome Measures
Name Time Method